Global Leukapheresis Devices Market: Key Developments
In April 2022, Asahi Kasei Medical Co., Ltd., a pharmaceutical corporation, has completed its acquisition of Bionova Scientific, LLC, a provider of contract process development services, and GMP, compliant contract manufacturing services to biopharmaceutical companies as announced on April 19, 2022.
On June 22, 2023, Haemonetics Corporation, a medical technology company focused on delivering innovative solutions to drive better patient outcomes, announced it has received clearance from the U.S. Food and Drug Administration (FDA) for advancements to its NexSys PCS plasma collection system. These include a new plasma collection bowl, featuring a patented design that optimizes performance, and new Express Plus Technology engineered to reduce procedure time.
On July 14, 2023, PredOmix is an innovation driven health tech company aim to pioneer cancer detection through our state-of-the-art multi-cancer early detection test, has unveiled one-of-its-kind innovative cancer detection blood test, OncoVeryx-F, capable of detecting early-stage cancers in women with a 98% accuracy. Backed by advanced metabolomics technology coupled with artificial intelligence (AI), the new-age innovation will enable the screening for early-stage cancers. Designed for women, the screening tool accurately diagnoses cancer before tumor development begins.
In January 2022, Cryoport, Inc., a global leader in temperature-controlled supply chain solutions for the life sciences industry, announced that it has entered into a strategic partnership with Cell Matters, S.A., to deliver to the life sciences industry end-to-end cryopreservation services for leukapheresis derived therapies supporting both autologous and allogeneic cell therapies. The companies will jointly develop the commercial approach for marketing these services.
Leukapheresis Devices Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients